Ex­clu­sive: New York biotech de­buts with $16M to find new ways to make sol­id can­cer cell ther­a­pies

A new biotech is com­ing out of stealth with $16 mil­lion to de­vel­op cell ther­a­pies for sol­id can­cers — an area where sci­en­tists have had lim­it­ed suc­cess.

OverT Bio (pro­nounced “overt,” not “over-T”) launched Mon­day, found­ed by New York Uni­ver­si­ty pro­fes­sor Neville San­jana and his for­mer post­doc Mat Legut.

The start­up is de­vel­op­ing a screen­ing plat­form which search­es for genes that, when over­ex­pressed, could help T cells be­come bet­ter agents against sol­id tu­mor can­cers. While there have been sev­er­al cell ther­a­pies ap­proved for blood can­cers, de­vel­op­ing them for sol­id tu­mors has proven far more chal­leng­ing. On­ly one cell ther­a­py has been ap­proved for a sol­id tu­mor can­cer: Io­vance’s tu­mor-in­fil­trat­ing lym­pho­cyte-based ther­a­py Am­tagvi, which won FDA ap­proval in Feb­ru­ary for ad­vanced melanoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER